Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Sales | 99,395 | 91,542 | 81,470 | 61,709 | 36,309 |
| Cost of Goods | 5,188 | 5,481 | 2,348 | 1,803 | -3,503 |
| Gross Profit | 94,207 | 86,061 | 79,122 | 59,906 | 39,812 |
| Operating Expenses | 200,964 | 182,623 | 129,785 | 123,764 | 159,974 |
| Operating Income | -106,569 | -96,081 | -50,315 | -63,055 | -120,665 |
| Interest Expense | 8,418 | 8,198 | 8,582 | 8,429 | 8,082 |
| Other Income | -20,775 | 80,338 | -9,635 | 97,214 | 10,131 |
| Pre-tax Income | -135,762 | -23,941 | -68,532 | 25,730 | -118,616 |
| Income Tax | 379 | 70 | 313 | 415 | 409 |
| Net Income Continuous | -136,141 | -24,011 | -68,845 | 25,315 | -119,025 |
| Net Income | $-136,141 | $-24,011 | $-68,845 | $25,315 | $-119,025 |
| EPS Basic Total Ops | -2.03 | -0.31 | -1.13 | 0.42 | -2.05 |
| EPS Basic Continuous Ops | -2.03 | -0.30 | -1.13 | 0.42 | -2.05 |
| EPS Diluted Total Ops | -2.03 | -0.30 | -1.13 | 0.41 | -2.05 |
| EPS Diluted Continuous Ops | -2.03 | -0.29 | -1.13 | 0.41 | -2.05 |
| EBITDA(a) | $-102,262 | $-92,317 | $-46,857 | $-59,721 | $-118,112 |